Skip to main content
Premium Trial:

Request an Annual Quote

Genedrive, Beckman Coulter Life Sciences Partner on Automated PCR Testing for SARS-CoV-2

NEW YORK – Genedrive announced on Thursday a collaboration with Danaher's Beckman Coulter Life Sciences to automate the entire laboratory PCR testing process for detecting SARS-CoV-2.

The two companies are validating the Genedrive 96 Sars-CoV-2 kit on the Biomek i7 automated workstation using saliva samples extracted with Indianapolis-based Beckman Coulter's RNAdvance viral extraction chemistry. Manchester, UK-based Genedrive has completed the initial evaluation of the extraction chemistry to confirm compatibility with Genedrive's test and is validating it in clinical saliva samples, it said.

Beckman Coulter's RNAdvance Viral XP is listed as an extraction method suitable for swab samples for use with the US Centers for Disease Control and Prevention's SARS-CoV-2 test, which received Emergency Use Authorization from the US Food and Drug Administration in February.

Financial and other terms of the deal were not disclosed.

"The combination of our ready-to-use chemistry with robotics and on-board RNA extraction would give laboratories a unique and rapid workflow that can achieve impressive throughput and result turnaround times," Genedrive CEO David Budd said in a statement. "We are both working to have the ongoing validation completed in approximately six weeks, with initial introduction in the USA at an already identified clinical laboratory."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.